WEBULL
WebtradeDownload

ANI Pharmaceuticals (ANIP) Wins FDA Approval, Is The 31% Undervaluation Still Real?

Simply Wall St · 1d ago

FDA approval puts ANI Pharmaceuticals on investors’ radar

ANI Pharmaceuticals (ANIP) received final FDA approval for its Abbreviated New Drug Application for Everolimus Tablets for Oral Suspension, a generic version of Afinitor Disperz that targets a U.S. market with about $123 million in annual sales.

At a share price of $72.58, ANI Pharmaceuticals has seen its 1-year total shareholder return decline 21.16%, even though the 5-year total shareholder return is 94.48%. This indicates that longer term holders have had a very different experience from those focused on recent momentum.

Capitalize on the fresh FDA catalyst at ANI Pharmaceuticals by scanning a curated list of resilient healthcare names in our 31 resilient stocks with low risk scores.

FDA approval can highlight a strong platform at ANI Pharmaceuticals. The harder question is whether a business showing revenue of US$978.4 million and net income of US$99.6 million is already fully reflected in a US$72.58 share price.

Most Popular Narrative: 31% Undervalued

Analysts following ANI Pharmaceuticals see a gap between the current $72.58 share price and a narrative fair value of $105.78, and they are tying that gap directly to how Cortrophin Gel, rare disease assets, and complex generics reshape the earnings mix over the next few years.

There is significant, untapped growth potential for Cortrophin Gel across core and emerging indications (neurology, nephrology, rheumatology, pulmonology, ophthalmology, and gout), with patient populations far below prior peaks and epidemiological data suggesting the addressable market could be several times larger due to an aging population and the rising prevalence of chronic diseases supporting multiyear revenue expansion.

See why 4 investors see ANI Pharmaceuticals as 31% undervalued.

Result: Fair Value of $105.78 (UNDERVALUED)

Still, the story around ANI Pharmaceuticals can change quickly if payer pushback on Cortrophin Gel intensifies or if first-to-market generic margins compress faster than expected.

Find out about the key risks to this ANI Pharmaceuticals narrative.

Next Steps

Mixed signals around ANI Pharmaceuticals can leave investors split, so consider doing your own research promptly and weigh both sides of the story using the 4 key rewards and 2 important warning signs.

Looking for more investment ideas beyond ANI Pharmaceuticals?

If the ANI Pharmaceuticals story has you thinking bigger, use the Simply Wall Street Screener to quickly surface fresh opportunities that might suit your approach.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.